GlobeNewswire by notified

PGS ASA: Invitation to Q4 2022 Earnings Release and Capital Markets Day

Share

January 19, 2023, Oslo, Norway: PGS will publish its Q4 2022 earnings release and capital markets day presentation on Thursday January 26, 2023 at approximately 07:00am Central European Time (CET).

The documents will be published on www.newsweb.no and on PGS’ website www.pgs.com. 

Presentation of the Q4 2022 results and Capital Markets Day material will begin the same day at 09:00am CET at Felix Conference Center, Bryggetorget 3 in Oslo.

Agenda*:
09:00        PGS strategy and seismic market outlook – Rune Olav Pedersen, President & CEO
09:30        Q4 2022 results and CMD financials – Gottfred Langseth, EVP & CFO
10:00        Q&A
10:15        Break
10:30        Sales & Services – Nathan Oliver, EVP
10:50        New Energy – Berit Osnes, EVP
11:05        Operations – Rob Adams, EVP
11:20        Q&A
11:30        Mingle lunch        

To attend the capital markets day in person please register on this LINK or copy and paste the address below into your browser:
https://forms.office.com/e/DUdYKFeiFZ

The event will be webcasted live. To log on to the webcast, copy and paste the link below into your browser, or go to PGS website www.pgs.com.

Webcast link:
https://channel.royalcast.com/landingpage/hegnarmedia/20230126_1/

Webcast Youtube link:
https://www.youtube.com/watch?v=-Dqj2GhdUH8

A replay of the webcast will be available on PGS’ website shortly after.
*Subject to changes.

FOR DETAILS, CONTACT:
Bård Stenberg, VP IR & Corporate Communication
Mobile: +47 99 24 52 35

***
PGS ASA and its subsidiaries (“PGS” or “the Company”) is an integrated marine geophysics company, which operates on a worldwide basis.PGS business supports the energy industry, including oil and gas, offshore renewables and carbon storage. The Company’s headquarter is in Oslo, Norway and the PGS share is listed on the Oslo stock exchange (OSE: PGS). For more information visit PGS’ website www.pgs.com.

--END--

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Kvika banki hf.: Financial Results for Q1 20242.5.2024 17:35:00 CEST | Press release

At a board meeting on 2 May 2024, the Board of Directors and the CEO approved the interim financial statements of the Kvika banki hf. (“Kvika” or “the bank”) group for the period 1 January to 31 March 2024. In Kvika’s financial statements for the period the insurance subsidiary TM tryggingar hf. (“TM”) is classified as held for sale. As a result, and in accordance with international financial reporting standards, the Group reports income from its insurance operations in a single line in the consolidated income statement as profit after tax from discontinued operations. The comparative figures of operations from 2023 have been restated accordingly. Highlights of the 3M 2024 Interim Financial Statements: Pre-tax profit, excluding TM insurance, amounted to ISK 1,215 million in Q1 2024, compared to ISK 895 million in Q1 2023 and increases by 36% from previous year.Post-tax profit of the group amounted to ISK 1,083 million in Q1 2024, compared to ISK 1,167 million in Q1 2023 and decreases b

Getmyboat and Visa Announce Exclusive Partnership for Premium Customers2.5.2024 17:21:04 CEST | Press release

MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Getmyboat, the world's leading boat rental and charter marketplace, has forged an exclusive strategic partnership with Visa's Platinum, Signature & Infinite cardholders. This unique collaboration is a significant milestone in enhancing the travel and leisure experiences of Visa's valuable customers, offering them unparalleled access to the world of boating adventures. Under this partnership, Visa cardholders will enjoy exclusive offers and benefits when they book a boat day through Getmyboat. These benefits include special discounts, priority booking, and access to unique packages tailored for Visa's premium cardholders. This initiative will enrich Visa's cardholders, providing them with unparalleled experiences and savings when exploring boating and yachting activities worldwide. "We are thrilled to partner with Visa to elevate the experiences of our mutual customers," said Doug Bird, VP of Sales & Business Development for Getmyboat

Scandinavian Tobacco Group reports first quarter 2024 results and maintains full-year guidance2.5.2024 17:15:00 CEST | Press release

Company Announcement No. 24/2024 Copenhagen, 2 May 2024 Interim report, 1 January - 31 March 2024 Scandinavian Tobacco Group reports first quarter 2024 results and maintains full-year guidance For the first quarter of 2024 Scandinavian Tobacco Group delivered a 1% decrease in reported net sales by DKK 1.9 billion with an EBITDA margin before special items at 17.2%. Net sales decreased 2% organically. Organic net sales growth in Handmade Cigars and Next Generation Oral was offset by decline in machine-rolled cigars & smoking tobacco. The EBITDA margin is impacted by declining volumes in a seasonally small quarter, mix changes and investments in growth. In the second quarter, the Group is expected to deliver organic net sales growth and a material improvement in the EBITDA-margin compared with the first quarter 2024. The full year guidance is maintained. First Quarter 2024 - Financial Performance Net sales of DKK 1,948 million (DKK 1,963 million) with 2% negative organic growth.EBITDA be

Inside information: Meriaura Energy to deliver a solar thermal plant for the district heating network operator of Lübeck in Germany2.5.2024 17:15:00 CEST | Press release

Meriaura Group Plc Company announcement, Inside information 2 May 2024 at 17.15 (CEST) Inside information: Meriaura Energy to deliver a solar thermal plant for the district heating network operator of Lübeck in Germany Meriaura Energy Ltd (“Meriaura Energy”) has signed a contract with Stadtwerke Lübeck Energie GmbH for the turn-key delivery of a solar thermal plant in Lübeck, Germany. The contract, valued at almost EUR 5 million, involves the construction of a solar thermal field of approximately 12,000 m2 in area and a thermal storage supplying heat to the district heating network. In accordance with the agreement, the execution of the project will start immediately, but the construction work of the facility in Germany can only start after the customer receives a building permit. The solar thermal plant is scheduled to be completed at the beginning of 2025. Meriaura Group Plc's CEO Kirsi Suopelto: "We have been working persistently in Germany, and it is a pleasure to once again conclu

Genmab Announces Financial Results for the First Quarter of 20242.5.2024 17:01:34 CEST | Press release

May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024An additional Phase 3 clinical trial was initiated, evaluating epcoritamab in combination with rituximab and lenalidomide compared to chemoimmunotherapy in previously untreated follicular lymphoma The U.S. FDA accepted for Priority Review the sBLA seeking to convert the accelerated approval of Tivdak® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapyGenmab announced the decision of its arbitra

HiddenA line styled icon from Orion Icon Library.Eye